Company news
Kymera Therapeutics, Inc. (NASDAQ:KYMR) news
Every Kymera Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
August 5, 2026
Kymera International Appoints Willson Ropp as Chief Executive Officer
July 29, 2026
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
July 28, 2026
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
July 27, 2026
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral...
July 7, 2026
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
June 24, 2026
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese De...
June 12, 2026
Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sa...
June 9, 2026
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
June 8, 2026
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 27, 2026
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatolog...
May 15, 2026
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
May 5, 2026
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 30, 2026
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
April 23, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Mode...
April 13, 2026
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
April 9, 2026
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Me...
March 28, 2026
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual...
March 10, 2026
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
February 26, 2026
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
February 19, 2026
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
February 4, 2026
Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
January 29, 2026
Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
January 13, 2026
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
January 6, 2026
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atop...
December 11, 2025
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Addit...
December 11, 2025
Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering
December 9, 2025
Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in ...
December 8, 2025
Kymera Therapeutics Announces Proposed Public Offering
December 8, 2025
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
December 5, 2025
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral...
November 25, 2025
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
November 24, 2025
Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update
November 4, 2025
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
November 3, 2025
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
October 28, 2025
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatolo...
October 27, 2025
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy ...
September 17, 2025
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
September 3, 2025
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 27, 2025
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
August 11, 2025
Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025
August 4, 2025
Kymera Therapeutics Announces Pricing of $250 Million Public Offering
June 26, 2025
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degra...
June 25, 2025
Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
June 25, 2025
Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, ...
June 2, 2025
Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025
May 30, 2025
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2025
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society Inte...
May 19, 2025
Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update
May 9, 2025
Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Ad...
May 9, 2025